Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 2

Status

Completed 5Terminated 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 808Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Recurrence 141Neoplasms, Plasma Cell 111Lymphoma 93Leukemia 91Neoplasms 81Burkitt Lymphoma 57Vomiting 51Lymphoma, Non-Hodgkin 50Immunoglobulin Light-chain Amyloidosis 50Lymphoma, Large B-Cell, Diffuse 44Nausea 38Lymphoma, Mantle-Cell 38Prostatic Neoplasms 31Lymphoma, Follicular 30Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Breast Neoplasms 25Lung Neoplasms 23Amyloidosis 21Leukemia, Biphenotypic, Acute 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Smoldering Multiple Myeloma 15

Interventions

Blood Specimen Collection 9Surveys and Questionnaires 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Prednisone 5Mammography 5Colonoscopy 5Biopsy 5Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Lenalidomide 4Biopsy, Fine-Needle 4pembrolizumab 3Tomography, X-Ray Computed 3Surgical Procedures, Operative 3Melphalan 3Liquid Biopsy 3Interviews as Topic 3Exercise 3Diagnostic Tests, Routine 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Urination 2Preoperative Exercise 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Disease × Dexamethasone × Clear all
NCT01857115 2024-11-13

wCCyd

European Myeloma Network B.V.

Phase 1/2 Completed
63 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02215980 2024-07-22

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Fondazione EMN Italy Onlus

Phase 3 Completed
210 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02204241 2023-07-03

CCD

European Myeloma Network B.V.

Phase 1/2 Completed
36 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡